K
Overview
Kandu is the merged entity formed by Kandu Health and Neurolutions to support stroke recovery. It combines the FDA-cleared non-invasive brain-computer interface (IpsiHand) with AI-supported telehealth for at-home rehabilitation and remote clinician guidance. The company differentiates itself by linking hardware-enabled therapy with ongoing remote care to provide a continuous rehab pathway from hospital discharge to home. Its goal is to create a seamless continuum of stroke care, from initial rehabilitation to long-term at-home recovery.
Work here?Claim your company
Simplify's take
What believers are saying
- February 2026 trial showed 4.5-point UEFM gain and 55.5% MCID achievement.
- January 2026 growth capital from K2 HealthVentures and Piper Sandler extended runway.
- CMS decision and HCPCS E0738 support home-use reimbursement for IpsiHand.
What critics are saying
- Kandu's revenue depends on one device; IpsiHand failure would cripple the company.
- CMS reimbursement rules or prior-authorization tightening would slow sales within 2026.
- If payers balk, Kandu stays a niche therapy and never reaches scale.
What makes Kandu unique
- Only FDA-cleared at-home BCI therapy pairs stroke rehab hardware with telehealth support.
- Kandu Medical Services adds remote monitoring, navigation, and clinician oversight after discharge.
- 2025 merger unified Neurolutions' IpsiHand and Kandu Health's care-delivery workflows.
Help us improve and share your feedback! Did you find this helpful?